Peptide Therapy for Women in Charleston: A Different Conversation

Ashley Harwyn, PA-C  |  A4M Board Certified  |  SC PA License  |  July 14, 2026  |  10 min read

Open almost any article about peptide therapy and notice who it is written for. The photos are of men in the gym. The language is about muscle, recovery, testosterone, performance. The entire category has been marketed, overwhelmingly, to men who lift. If you are a woman who has heard peptides mentioned and felt that none of it seemed aimed at you, you were reading the room correctly. This guide is the other conversation: what peptide therapy actually means for women, what the evidence genuinely supports, where it is still thin, and who is and is not a candidate. It is written to be honest rather than promotional, because on this topic honesty is in short supply.

What is peptide therapy, and why is it marketed mostly to men?

Peptides are short chains of amino acids that act as signaling molecules in the body, telling cells and systems what to do. Some are legitimate, FDA-approved medicines. Many others are sold online in a gray market with far more marketing than evidence behind them, a problem serious enough that the certification body LegitScript documented a 308% jump in problematic peptide advertising in a single year. We wrote a full guide on how to tell whether a peptide clinic is legitimate, and it is worth reading alongside this one.

As for why the marketing skews so heavily male, the answer is partly cultural and partly historical. Peptides entered popular awareness through bodybuilding and men's performance circles, and the marketing simply stayed there. But the underlying biology is not male-specific, and a few peptides have real relevance to women's health. The problem is that the honest, women-centered version of this conversation almost never gets published, because it is less profitable than the hype. So let us have it.

Which peptides actually have evidence for women?

Here is the single most important thing to understand, and the thing the marketing works hardest to blur: of all the peptides discussed in women's wellness circles, exactly one currently holds an FDA-approved indication for a women's health condition. The rest are either preliminary, off-label, or unproven for the uses they are marketed for. Knowing which is which is the whole game.

PT-141: the one with FDA approval

PT-141, sold as Vyleesi, is the peptide with the strongest standing in women's health, because the FDA approved it in June 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder, or HSDD, in premenopausal women^[1]. That is a specific and meaningful approval. HSDD is defined not simply as low sexual desire but as low desire that causes real personal distress, and it affects a significant number of women who have historically had almost no evidence-based options.

What makes PT-141 different from older approaches is where it works. Rather than acting on blood flow the way medications for men's sexual function do, it acts centrally, in the brain, on the melanocortin system that influences sexual motivation^[1]. Its approval was based on two identical Phase 3 randomized, placebo-controlled trials that together enrolled 1,247 premenopausal women, followed by a 52-week extension study^[1][3]. That is a genuine evidence base, not a marketing claim.

GLP-1 medications: the other evidence-backed peptides

The other peptides with substantial evidence in women are the GLP-1 medications, semaglutide and tirzepatide, which are technically peptide-based drugs. Their evidence for metabolic health and weight management is extensive and FDA-recognized, and they carry particular relevance for women with conditions like PCOS. We treat those in depth in our medical weight loss guide rather than here, but they belong on any honest list of peptides that actually work for women.

Everything else: the honest caveat

The rest of the peptides that dominate the marketing sit on very different regulatory footing, and lumping them together is exactly the kind of blurring you should be wary of. Some, like sermorelin and ipamorelin, can be prescribed off-label through a licensed compounding pharmacy under medical supervision, though their evidence for the uses they are marketed for is limited. Others, like BPC-157 and TB-500, are unapproved and sit in an unsettled regulatory gray zone; as of 2026 the FDA is actively reviewing whether BPC-157 may be legally compounded at all. None of these has the rigorous, women-specific clinical trial support that PT-141 has for its narrow indication. That does not make them all equivalent, but it does mean that any clinic presenting them as proven, or glossing over the difference between an off-label prescription and an unapproved compound, is getting well ahead of the evidence, and you should treat that as a signal about the clinic.

Is peptide therapy for women safe?

Safety depends entirely on three things: which peptide, from where, and under whose supervision. Those three questions matter far more than the word "peptide" itself.

A peptide that is FDA-approved, sourced through a licensed compounding pharmacy, and prescribed by a clinician who has evaluated you is a fundamentally different proposition from the same molecule ordered off a website that ships without asking a single question. The vial might look identical. The risk profile is not remotely the same. This is why the sourcing question is not a technicality but the center of the whole issue, and why independent certification of a clinic's medication sourcing carries real weight.

Even the FDA-approved options carry genuine cautions. PT-141, for example, is not appropriate for women with uncontrolled high blood pressure or known cardiovascular disease, and it raises blood pressure transiently after each dose^[1]. Real medicine has real contraindications, and a clinic that never mentions any is not being reassuring, it is being incomplete.

Why is this "a different conversation"?

Because the honest version of it centers women, and it tells the truth about limits. The peptide industry has spent years selling women a male-coded fantasy of optimization, long lists of compounds promising energy, recovery, libido, and anti-aging, with the evidence quietly omitted. A different conversation looks like this: one peptide has solid FDA approval for one specific women's condition, the GLP-1 medications have strong metabolic evidence, and the rest range from preliminary to unproven for women. That is less exciting than the marketing. It is also true.

It is worth naming why this matters so much for women specifically. Women's sexual health, hormonal health, and metabolic health have been underserved by medicine for decades, and that neglect created exactly the vacuum that hype fills. The answer to being underserved is not to swing to the opposite extreme and accept unproven promises. It is to demand the same standard of evidence, honesty, and supervision that any other area of medicine should provide. That standard is the entire point of how we practice.

Who is, and who is not, a candidate?

A clinic willing to tell you when the answer is no is worth more than one that says yes to everyone, so let me be specific about both sides.

A woman may be a reasonable candidate for a peptide conversation if she has a genuine, well-defined concern that maps to a peptide with actual evidence. Distressing low sexual desire that is not explained by relationship, medication, or medical factors is the clearest example, because that is precisely what PT-141 was studied and approved for. A woman navigating the metabolic changes of midlife or PCOS may be a candidate for a GLP-1 conversation grounded in real testing. In both cases, candidacy is established by evaluation, not by a website checkout.

There are also women for whom the honest answer is no, or not yet. PT-141 is not appropriate for a woman with uncontrolled high blood pressure or known cardiovascular disease^[1]. No peptide is a substitute for addressing an underlying hormonal or thyroid issue that is actually driving the symptom, and reaching for one before that groundwork is done usually disappoints. And any woman being sold a stack of unproven compounds for vague goals like general "anti-aging" or "optimization" is not a candidate for that stack, because the evidence to justify it does not exist. Recognizing when a peptide is the wrong tool is as much a part of good care as knowing when it is the right one.

How Solcara approaches peptides for women in Charleston

Our approach begins by taking your concerns seriously and then being straight with you about what can and cannot be responsibly addressed with a peptide. For some women, that means a conversation about PT-141 for genuine HSDD, with full disclosure of its benefits, its side effects, and its approval status. For others, it means a GLP-1 conversation grounded in metabolic testing. For many, it means explaining honestly that the peptide they read about does not have the evidence to justify it, and pointing toward something that does.

That means real evaluation before any prescription: a proper history, appropriate lab work, and screening for the contraindications that matter. It means medications sourced only through licensed compounding pharmacies, never a gray-market supplier. And it means placing any peptide conversation inside the larger picture of your hormonal and metabolic health, because for women especially, symptoms like low libido, fatigue, and difficult body composition are usually connected to something broader than a single molecule can fix. If you would rather know the truth than be sold a protocol, that is the conversation we are set up to have, whether you are coming to us in Mount Pleasant or downtown at The Longevity Club.